Population Pharmacokinetic and Exposure-Response Analyses for Efficacy and Safety of Risankizumab in Patients With Active Crohn's Disease.
Journal
Clinical pharmacology and therapeutics
ISSN: 1532-6535
Titre abrégé: Clin Pharmacol Ther
Pays: United States
ID NLM: 0372741
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
received:
01
09
2022
accepted:
11
12
2022
pubmed:
20
12
2022
medline:
17
3
2023
entrez:
19
12
2022
Statut:
ppublish
Résumé
The population pharmacokinetics (PK) of risankizumab and exposure-response relationships for efficacy and safety in patients with Crohn's disease (CD) were characterized using data from phase II and III studies to support dosing regimen selection. A two-compartment model with first-order absorption and first-order elimination adequately described risankizumab PK. Covariates including sex, baseline fecal calprotectin, corticosteroid use, baseline creatinine clearance, body weight, and baseline albumin were statistically correlated with risankizumab clearance, but their impact on exposure was not clinically relevant for efficacy or safety. Exposure-response analyses showed that exposures associated with the 600 mg intravenous (i.v.) induction dose at Weeks 0, 4, and 8 achieved a near maximal response for all efficacy end points evaluated, with negligible added benefit from the 1,200 mg i.v. regimen. By Week 52 of the maintenance treatment, trends of higher responses were observed for the exposure range associated with the 360 mg subcutaneous (s.c.) every-8-weeks (Q8W) regimen for most of the evaluated efficacy end points, particularly for the more stringent end points, such as endoscopic remission and ulcer-free endoscopy. Exposure-response analyses for safety did not identify any apparent relationship between exposure and safety. These results supported the final dose recommendation of 600 mg i.v. at Weeks 0, 4, and 8, followed by 360 mg s.c. at Week 12 and Q8W thereafter in patients with CD.
Substances chimiques
risankizumab
90ZX3Q3FR7
Antibodies, Monoclonal
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
839-850Informations de copyright
© 2022 AbbVie Inc. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.
Références
Hanauer, S.B. & Sandborn, W. Management of Crohn's disease in adults. Am. J. Gastroenterol. 96, 635-643 (2001).
Loftus, E.V. Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 126, 1504-1517 (2004).
Singh, S. et al. Selective targeting of the IL23 pathway: generation and characterization of a novel high-affinity humanized anti-IL23A antibody. MAbs 7, 778-791 (2015).
Feagan, B.G. et al. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet 389, 1699-1709 (2017).
Feagan, B.G. et al. Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study. Lancet Gastroenterol. Hepatol. 3, 671-680 (2018).
Ferrante, M. et al. Long-term safety and efficacy of Risankizumab treatment in patients with Crohn's disease: results from the phase 2 open-label extension study. J. Crohns Colitis 15, 2001-2010 (2021).
D'Haens, G. et al. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet 399, 2015-2030 (2022).
Ferrante, M. et al. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet 399, 2031-2046 (2022).
Suleiman, A.A., Khatri, A., Minocha, M. & Othman, A.A. Population pharmacokinetics of the Interleukin-23 inhibitor Risankizumab in subjects with psoriasis and Crohn's disease: analyses of phase I and II trials. Clin. Pharmacokinet. 58, 375-387 (2018).
Suleiman, A.A., Minocha, M., Khatri, A., Pang, Y. & Othman, A.A. Population pharmacokinetics of Risankizumab in healthy volunteers and subjects with moderate to severe plaque psoriasis: integrated analyses of phase I-III clinical trials. Clin. Pharmacokinet. 58, 1309-1321 (2019).
Patel, K.V., Darakhshan, A.A., Griffin, N., Williams, A.B., Sanderson, J.D. & Irving, P.M. Patient optimization for surgery relating to Crohn's disease. Nat. Rev. Gastroenterol. Hepatol. 13, 707-719 (2016).
Frøslie, K.F., Jahnsen, J., Moum, B.A. & Vatn, M.H. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 133, 412-422 (2007).
Klenske, E., Bojarski, C., Waldner, M., Rath, T., Neurath, M.F. & Atreya, R. Targeting mucosal healing in Crohn's disease: what the clinician needs to know. Therap. Adv. Gastroenterol. 12, 1756284819856865 (2019).
Rutgeerts, P., Vermeire, S. & Van Assche, G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut 56, 453-455 (2007).
Sandborn, W.J. et al. Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases. J. Crohns Colitis 8, 927-935 (2014).
Ferrante, M. et al. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. Gastroenterology 145, 978-86.e5 (2013).
Vuitton, L. et al. IOIBD technical review on endoscopic indices for Crohn's disease clinical trials. Gut 65, 1447-1455 (2016).
Schnitzler, F. et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-Centre cohort. Gut 58, 492-500 (2009).
Baert, F. et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 138, 463-468; quiz e10-1 (2010).
Rutgeerts, P. et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest. Endosc. 63, 433-442; quiz 64 (2006).